Trovafloxacin is a topic covered in the Johns Hopkins ABX Guide.
To view the entire topic, please sign in or purchase a subscription.
Official website of the Johns Hopkins Antibiotic (ABX), HIV, Diabetes, and Psychiatry Guides, powered by Unbound Medicine. Johns Hopkins Guide App for iOS, iPhone, iPad, and Android included. Explore these free sample topics:
-- The first section of this topic is shown below --
INDICATIONS
FDA
FDA
- Before pulled from the U.S. market for hepatotoxicity reasons, the use of trovafloxacin was reserved for use only if the patient meets all of the following criteria:
- Has at least one of the following infections that is judged by the treating physician to be serious and life- or limb-threatening:
- Nosocomial pneumonia
- Community acquired pneumonia
- Complicated intra-abdominal
- Gynecologic, pelvic and skin infections
- Receives initial therapy in an in-patient heath care facility (i.e., hospital or long-term nursing care facility).
- The treating physician believes that, even given the new safety information, the benefit of the product for the patient outweighs the potential risk.
- Use of trovafloxacin was limited to 14 days or less.
- Has at least one of the following infections that is judged by the treating physician to be serious and life- or limb-threatening:
NON-FDA APPROVED USES
NON-FDA APPROVED USES
-- To view the remaining sections of this topic, please sign in or purchase a subscription --
Last updated: May 1, 2017
Citation
TY - ELEC
T1 - Trovafloxacin
ID - 540567
A1 - Avdic,Edina,Pharm.D.
AU - Pham,Paul,Pharm.D.
Y1 - 2017/05/01/
PB - Johns Hopkins ABX Guide
UR - https://www.unboundmedicine.com/medline/view/Johns_Hopkins_ABX_Guide/540567/all/Trovafloxacin
ER -